6,875 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Kentucky Trust Co

Kentucky Trust Co purchased a new position in Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 6,875 shares of the biopharmaceutical company’s stock, valued at approximately $389,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Viewpoint Capital Management LLC grew its position in Bristol-Myers Squibb by 8.4% in the fourth quarter. Viewpoint Capital Management LLC now owns 33,155 shares of the biopharmaceutical company’s stock worth $1,875,000 after acquiring an additional 2,579 shares in the last quarter. TFB Advisors LLC grew its position in Bristol-Myers Squibb by 14.9% in the fourth quarter. TFB Advisors LLC now owns 4,787 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 621 shares in the last quarter. Signet Investment Advisory Group Inc. grew its position in Bristol-Myers Squibb by 2.3% in the fourth quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company’s stock worth $467,000 after acquiring an additional 189 shares in the last quarter. Authentikos Wealth Advisory LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter worth about $266,000. Finally, Leavell Investment Management Inc. lifted its stake in Bristol-Myers Squibb by 7.1% in the fourth quarter. Leavell Investment Management Inc. now owns 39,008 shares of the biopharmaceutical company’s stock worth $2,206,000 after purchasing an additional 2,582 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on BMY. Citigroup raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price objective for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Truist Financial raised their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $55.99 on Wednesday. The company has a 50-day moving average of $57.48 and a two-hundred day moving average of $53.97. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The stock has a market cap of $113.56 billion, a P/E ratio of -12.67, a PEG ratio of 2.13 and a beta of 0.45. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, research analysts predict that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.43%. The ex-dividend date was Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.